CYP3A5
MOLECULAR TARGETcytochrome P450 family 3 subfamily A member 5
CYP3A5 (cytochrome P450 family 3 subfamily A member 5) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CYP3A5
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | clobetasol propionate | 2.56 | 12 |
| 2 | Ritonavir | 1.79 | 5 |
| 3 | Voriconazole | 1.39 | 3 |
| 4 | cbd | 0.69 | 1 |
| 5 | cannabidiol | 0.69 | 1 |
About CYP3A5 as a Drug Target
CYP3A5 (cytochrome P450 family 3 subfamily A member 5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented CYP3A5 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CYP3A5 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.